Navigation Links
Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
Date:4/29/2009

Conference Call and Webcast Scheduled for Wednesday, May 6, 2009

SAN DIEGO, April 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2009 financial results after the Nasdaq market closes on Tuesday, May 5, 2009. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday morning, May 6, 2009 at 8:30 a.m. Eastern Daylight Time (5:30 a.m. Pacific Daylight Time).

Participants can access the live conference call by dialing 1-800-895-0198, (US) or 785-424-1053 (International) using the conference ID: 7NEURO. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com

If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-688-7339 (US) or 402-220-1347 (International) using the conference ID: 7NEURO. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
2. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
3. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
6. Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
7. Pressure BioSciences, Inc. Provides Corporate Update
8. BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
9. Cell Biosciences Announces First UK System Sale
10. Regado Biosciences to Present at the 2009 Wharton Healthcare Business Conference
11. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Hills, CA (PRWEB) September 16, 2014 ... announce the launch of ACLsurgeryLA.com , a specialty ... ACL injuries. As an avid sports lover and ... options for treatment and recovery from injuries to maintain ... opportunity to offer patients a resource dedicated specifically to ...
(Date:9/16/2014)... NY (PRWEB) September 16, 2014 Registration ... Run For The Warriors®, a 10K, 5K, and 1-mile ... The race is sponsored by Local 338 RWDSU/UFCW, the ... will begin at the Town of Babylon Town Hall ... http://www.hopeforthewarriors.org/2014LIRun . The run is organized by Hope ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 *To find out ... visit Achieve Clinical Research on the web ( http://www.achieveclinical.com/trial/pneumonia-vaccine/ ) ... who qualify:, There is no cost ... , Compensation may be provided for time and ... and influenza are the eighth leading cause of death in ...
(Date:9/16/2014)... DeLand, Florida (PRWEB) September 16, 2014 ... clinical trials being conducted in DeLand, FL can visit ... or contact them directly at (386) 785-2404. , Why ... of the most widespread viral diseases infecting mankind. While ... past, these colds still account for more annual visits ...
(Date:9/16/2014)... 2014 justthoughtyoushouldknow.org , popular ... launches their new site today. The new site ... at making information easier to find, ingest, and ... into one-page, easy-to-read pages the information that we ... Virginia Downie, retired college professor and founder of ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 3Health News:JustThoughtYouShouldKnow.org Debuts New Website 2
... Dec. 6 Arete Therapeutics Inc., a,privately-held biopharmaceutical ... of cardiovascular, inflammatory and,metabolic diseases, today announced the ... directors., "We are very pleased to welcome ... and operational insights will be of great benefit ...
... Name Also Unveiled in Ongoing Preparation for ... Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical company ... cancer, announced that new data,including four-year follow-up ... of Specifid(TM) (formerly FavId(R)), will be reported ...
... Oncology, the nation,s leading,oncology services company, today named ... and chief operating officer. The appointment,becomes effective on ... experience, combined with his work in,large diversified healthcare ... Broussard, president of US Oncology.,"His proven success in ...
... first increase in U.S.,teen pregnancy rates, WASHINGTON, Dec. ... pregnancy rates in the United States over the,last fourteen ... should not come as a surprise since the dual ... -- the decline in sexual,initiation and more effective use ...
... http://feeds.feedburner.com/OrthoWomensHealthAndUrology , RARITAN, NJ, December 5 Jane ... about the Pill as part of The Modern,Girl,s Guide ... Girl,s Guide to the Pill, When: The Podcast ... Where: http://feeds.feedburner.com/OrthoWomensHealthAndUrology , How: Go to ...
... With the popularity of,fillers becoming mainstream, it,s no ... prevent facial wrinkles. Dr. Arnold Klein, world,renowned cosmetic ... "Fillers such as Artefill, Radiesse and Sculptra contain ... tissue, all of,these products can cause foreign body ...
Cached Medicine News:Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 3Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 4Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 5Health News:US Oncology Appoints Glen Laschober EVP & Chief Operating Officer 2Health News:Facial Deformity Danger? 2
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- ... affects persons of all ages, but most commonly ... condition characterized by narrowing of the airways, leading ... the lungs come into contact with endogenous and ... of events, such as swelling of the airways, ...
(Date:9/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... owned subsidiary, Valeant Pharmaceuticals International, will redeem all of ... 6.75% Senior Notes due 2017, CUSIP Nos. 91911XAL8, U9098VAD4 ... has mailed an irrevocable notice of redemption for the ... of the irrevocable notice of redemption with respect to ...
(Date:9/15/2014)... , Sept. 15, 2014  Decision Resources ... Physician™ 2014, finds that online information and ... brands to differentiate their offering and support ... device purchasing decisions rely on websites, mobile ... about devices—and these physicians are looking to ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2Physician device decision-makers show strong demand for device manufacturer digital content and support 2Physician device decision-makers show strong demand for device manufacturer digital content and support 3
... A recently published University of Nevada study indicates that ... the air to reduce the impact of oxidation on essential ... the study showed similar impacts on Vitamin C.   ... human milk and infant formula using varied bottle systems ," ...
... LA JOLLA, Calif., Dec. 13, 2010 Anaphore ... into a partnership with Mitsubishi Tanabe Pharma Corporation (Osaka, ... novel protein therapies for autoimmune disease . ... platform technology, which generates novel trivalent proteins called ...
Cached Medicine Technology:Published Study Concludes: Vented Baby Bottles Protect Essential Nutrients in Breast Milk and Formula 2Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders 2Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders 3
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTN/1Q-CAB chairs are recommended for ... clean room, static control, health care ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With reinforced ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
Medicine Products: